Molloyhenry2366

in planning target volume (PTV) coverage and OAR doses, but VMAT had less number of monitor units and shorter treatment time.

Of all breast cancers, triple-negative and HER-2 positive are the most aggressive breast cancer subtypes with a high risk of recurrence and worse prognosis. The study's purpose was to further assess the molecular mechanisms underlying aggression of breast cancer.

The microarray gene expression datasets of GSE29431 and GSE53752 were obtained from the GEO (Gene Expression Omnibus) database, which include HER-2 positive breast cancer, triple-negative breast cancer (TNBC) and normal breast tissue samples. Differentially expressed genes (DEGs) were determined using the LIMMA package of R software and subsequently functional enrichment analysis were performed by the ClusterProfiler package in the R platform. The STRING database was used to construct a protein-protein interaction (PPI) network. The most significant module and key genes were identified by Cytoscape software. Utilizing the Kaplan-Meier plotter and UALCAN database, we defined the key genes associated with prognotic values and molecular subtypes as nes promoted the individualized and comprehensive treatment.

Aberrant DNA methylation in promoter regions has been found in many cancers, including breast cancer (BC). A Methylation Specific PCR (MSP) was applied in breast Fine Needle Aspiration Biopsy (FNAB) material, which has been rarely used in the literature, to estimate the methylation frequencies of CND2, APC, HIN1 & CDH13 and to assess whether this multiplex methylation panel can be possibly used as an indicator-biomarker for BC detection in a Greek population.

A total of 104 participants were subjected to FNAB and both cytological evaluation and epigenetic analysis were carried out. DNA was extracted from FNAB samples and was subjected to bisulfite conversion. MSP was carried out with primers specific for either the methylated or unmethylated status for each gene. The final MSP products were analyzed in 2% agarose gels with electrophoresis.

Hypermethylation was observed in 74%, 69.2%, 59.6% and 63.4% of the samples for CND2, HIN1, APC and CDH13, respectively. CND2 was the most hypermethylated in C5 cases (90%) and APC and HIN1 in C4 cases (88.2%). A significant correlation between histologic evaluation and the methylation frequencies for all 4 genes was calculated (p<0.001). Odds ratio for breast malignancy was 8.267 for CND2, 5.235 for APC, 7.852 for HIN1 and 22.920 for CDH13, underlying that their methylation is positively related to breast malignancy. Also, it seems that the combination of all genes into a multiplex methylation panel has significantly higher SP and PPV than any single gene methylation.

Our study shows that breast FNAB combined with methylation data from the collected aspirates has a promising potential as a biomarker for the early detection of BC risk in women with suspicious lesions.

Our study shows that breast FNAB combined with methylation data from the collected aspirates has a promising potential as a biomarker for the early detection of BC risk in women with suspicious lesions.

To explore the efficacy and safety of oncoplastic breast-conserving surgery (OBCS) combined with intraoperative radiotherapy (IORT) in the treatment of early breast cancer (EBC).

The clinical data of 114 EBC patients treated in our hospital from January 2014 to May 2016 were retrospectively analyzed. The patients were divided into OBCS + IORT group (OBCS group, n=32) and standard BCS (SBCS) + IORT group (SBCS group, n=82) according to different treatment methods. The operation-related indexes, the weight of breast tissues resected, the surgical margin, the postoperative cosmetic effect on affected breasts and quality of life, the incidence of postoperative complications, postoperative tumor recurrence and patient's survival were compared between the two groups.

The operation time of patients in OBCS group was significantly longer than in SBCS group, the amount of intraoperative blood loss and postoperative drainage was significantly smaller than in SBCS group, and the postoperative hospital stay was obvt of EBC, which can not only effectively ensure the surgical margin in BCS and reduce the incidence of surgical complications, but also obtain a better cosmetic effect and satisfaction with breast appearance, and improve the postoperative quality of life of patients.

To explore the efficacy and safety of everolimus combined with endocrine therapy in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER-2)-negative advanced breast cancer.

The clinical information of 108 patients with HR-positive/HER-2-negative advanced breast cancer, who were admitted to and treated in our hospital from June 2014 to June 2016, was retrospectively analyzed. Of them, 54 patients were treated with everolimus combined with endocrine drugs (Everolimus group), while the other 54 patients underwent endocrine monotherapy (Control group). The clinical response rate and incidence of adverse reactions were compared between the two groups of patients, and the patients were followed up to record survival. Besides, the possible influencing factors for progression-free survival (PFS) were analyzed.

The objective response rate (ORR) was 22.2% and 14.8%, respectively, in everolimus group and the Control group, while the clinical benefit rate (CBR) was 66.7% and 37 prognostic factors for PFS.

Everolimus combined with endocrine therapy has significant clinical efficacy in patients with HR-positive/HER-2-negative advanced breast cancer, and can effectively improve the survival of patients with tolerable adverse reactions. PR+, absence of visceral metastases and sensitivity to endocrine therapy are the protective prognostic factors for PFS.

Breast cancer accounts for a significant proportion of cancer burden among women world over. DLinKC2DMA Concerning breast cancer treatment, there are only few chemotherapeutic agents available, which also have serious side effects. The present study was thus designed to explore in vitro the antitumor effects of ambrosin sesquiterpene lactone against human drug-resistant breast cancer cells (MDA-MB-231).

WST-1 assay was used to determine cell viability. The fact that ambrosin induced apoptosis was studied through acridine orange (AO)/ethidium bromide (EB) staining using fluorescence microscopy as well as using flow cytometry in association with annexin-v/propidium iodide (PI) staining. Furthermore, western blot assay was used to study effects of ambrosin on apoptosis-related protein expressions including Bax and Bcl-2, as well as to study the effects on numerous caspases and Akt/β-Catenin Signaling Pathway. The effects on reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were evaluated by flow cytometry.